CCI
FATE icon

Columbus Circle Investors’s Fate Therapeutics FATE Stock Holding History

Columbus Circle Investors’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		$18.4M Sell
202,279
-41,458
-17% -$2.57M 0.81% 41
2020
Q3 		$9.74M Sell
243,737
-27,578
-10% -$963K 0.42% 87
2020
Q2 		$9.31M Buy
271,315
+236,065
+670% +$7.04M 0.37% 91
2020
Q1 		$783K Sell
35,250
-250
-0.7% -$6.32K 0.04% 138
2019
Q4 		$695K Sell
35,500
-48,605
-58% -$772K 0.03% 145
2019
Q3 		$1.31M Sell
84,105
-31,427
-27% -$602K 0.05% 138
2019
Q2 		$2.35M Buy
115,532
+9,872
+9% +$178K 0.06% 136
2019
Q1 		$1.86M Sell
105,660
-96,066
-48% -$1.52M 0.05% 131
2018
Q4 		$2.59M Sell
201,726
-108,893
-35% -$1.52M 0.07% 129
2018
Q3 		$5.06M Buy
310,619
+51,406
+20% +$608K 0.1% 151
2018
Q2 		$2.94M Buy
259,213
+36,655
+16% +$404K 0.06% 175
2018
Q1 		$2.17M Buy
+222,558
New +$2.13M 0.04% 177

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
JJIJ
Johnson & Johnson Innovation - JJDC New Brunswick, New Jersey $978M AUM 102.17% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Columbus Circle Investors's FATE Position: Q4 2020 in Review

Columbus Circle Investors reduced its Fate Therapeutics (FATE) stake by 17% in Q4 2020, selling an estimated $2.57M and leaving 202,279 shares worth $18.4M. The position accounts for 0.81% of the portfolio, ranked #41.

Columbus Circle Investors first reported a position in FATE in Q1 2018 and has held it in 12 quarters since. 248 funds tracked by Wall St. Rank hold FATE as of Q4 2020.

  • Columbus Circle Investors held 202,279 shares of Fate Therapeutics worth $18.4M as of Q4 2020.
  • Columbus Circle Investors sold 41,458 Fate Therapeutics shares in Q4 2020, an estimated $2.57M.
  • Fate Therapeutics made up 0.81% of Columbus Circle Investors's portfolio in Q4 2020, its #41 holding.
  • Columbus Circle Investors first reported a position in Fate Therapeutics in Q1 2018 and has held it in 12 quarters since.
  • 248 funds tracked by Wall St. Rank held Fate Therapeutics as of Q4 2020.

Based on Columbus Circle Investors's 13F filing for Q4 2020, filed 20 Jan 2021.